Cat. No.: HY-10006

Flavopiridol Hydrochloride

(Synonyms: Alvocidib Hydrochloride; L86-8275 Hydrochloride; HMR-1275 Hydrochloride)

54 Cited Publications

Customer Review

Based on 54 publication(s) in Google Scholar

Flavopiridol Hydrochloride (Alvocidib Hydrochloride) is a broad inhibitor of CDK, competing with ATP to inhibit CDKs including CDK1, CDK2, CDK4 with IC₅₀s of 30, 170, 100 nM, respectively.

For research use only. We do not sell to patients.

Purity: 99.73%
CAS No.: 131740-09-5
Formula: C₂₁H₂₁Cl₂NO₅
Molecular Weight:438.30

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

Flavopiridol Hydrochloride Chemical Structure

CAS No.: 131740-09-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (54)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[3]

CDK1/Cyc B1

30 nM (IC₅₀)

CDK2/Cyc E

170 nM (IC₅₀)

CDK4/Cyc D1

100 nM (IC₅₀)

MAP

19000 nM (IC₅₀)

PKC

14000 nM (IC₅₀)

EGFR

22000 nM (IC₅₀)

All CDK Isoforms :

All HIV Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Caco-2	CC₅₀	0.06 μM Compound: ALVOCIDIB	Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay	10.21203/rs.3.rs-23951/v1
Caco-2	IC₅₀	0.59 μM Compound: ALVOCIDIB	Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging	10.21203/rs.3.rs-23951/v1

In Vitro

Flavopiridol (2 μM) robustly induces a distinct pattern of ER stress in CLL cells that contributes to cell death through IRE1-mediated activation of ASK1 and possibly downstream caspases^[1]. Flavopiridol results in potent upregulation of a number of PRGs in treatments lasting 4-24 h. Flavopiridol has and immediate and long-term effect on the expression of several PRGs. In serum starved cells re-stimulated with serum, flavopiridol also inhibits the expression of these genes, but subsequently, JUNB, GADD45B and EGR1 are upregulated in the presence of flavopiridol^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 131740-09-5
Appearance Solid
Molecular Weight 438.30
Formula C₂₁H₂₁Cl₂NO₅
Color Light yellow to khaki
SMILES

O=C1C2=C(C=C(C([C@]3([H])[C@H](O)CN(C)CC3)=C2OC(C4=CC=CC=C4Cl)=C1)O)O.[H]Cl
Synonyms

Alvocidib Hydrochloride; L86-8275 Hydrochloride; HMR-1275 Hydrochloride
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

Publications (54)

All Cell Imaging/StainingCell Proliferation/Viability AssayIn Vivo Efficacy StudyIHCFlow CytometryWB

Sort by:

Journal Impact Factor

Nature

Mapping and engineering RNA-driven architecture of the multiphase nucleolus. [Abstract]

2025 Aug;644(8076):557-566. PMID: 40604277

Flavopiridol Hydrochloride purchased from MedChemExpress. Usage Cited in: Nature. 2025 Aug;644(8076):557-566. [Abstract]

Nucleolar morphology (IF for RPA194, FBL, and NPM1 for FC, DFC and GC) in DMSO (-FVP) and after 30-90 min of 2 μM FVP (Flavopiridol) treatment.
Nature

Rapid unleashing of macrophage efferocytic capacity via transcriptional pause release. [Abstract]

2024 Apr;628(8007):408-415. PMID: 38480883

Flavopiridol Hydrochloride purchased from MedChemExpress. Usage Cited in: Nature. 2024 Apr;628(8007):408-415. [Abstract]

Immunoblotting showing CDK9, Ser2P and β-Actin protein levels in macrophages treated with either DMSO or Flavopiridol (10 μM) for 30 min. n = 3 independent experiments.
Cell

BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. [Abstract]

2021 Apr 15;184(8):2167-2182.e22. PMID: 33811809
Cancer Discov

Transcription Elongation Machinery Is a Druggable Dependency and Potentiates Immunotherapy in Glioblastoma Stem Cells. [Abstract]

2021 Oct 6;candisc.1848.2020. PMID: 34615656
Nat Biomed Eng

Inhibition of LARP4-mediated quiescence exit of naive CD4+ T cells ameliorates autoimmune and allergic diseases. [Abstract]

2025 Oct 16. PMID: 41102557
Nat Commun

CDK9 recruits HUWE1 to degrade RARα and offers therapeutic opportunities for cutaneous T-cell lymphoma. [Abstract]

2024 Dec 5;15(1):10594. PMID: 39632829
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Acta Pharm Sin B

Engineering prodrug nanomicelles as pyroptosis inducer for codelivery of PI3K/mTOR and CDK inhibitors to enhance antitumor immunity. [Abstract]

2022 Jul;12(7):3139-3155. PMID: 35865097

Flavopiridol Hydrochloride purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2022 Jul;12(7):3139-3155. [Abstract]

Flavopiridol (Flav; 0-1 μg/mL; 24 h). MTT assay-derived curves of PF, Flav, PF + Flav and PNM in 4T1 cells after 24 h of treatment.

Flavopiridol Hydrochloride purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2022 Jul;12(7):3139-3155. [Abstract]

Flavopiridol (Flav; 5 mg/kg; i.v.). Schedule of establishment of the 4T1 tumor-bearing mouse model and different treatments. Average tumor growth curves of the mice treated with PBS, PF, Flav, PF + Flav and PNM.

Flavopiridol Hydrochloride purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2022 Jul;12(7):3139-3155. [Abstract]

Flavopiridol (Flav; 5 mg/kg; i.v.). Representative pictures of HE staining and Ki-67 staining in tumor sections of different groups.

Flavopiridol Hydrochloride purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2022 Jul;12(7):3139-3155. [Abstract]

Flavopiridol (Flav; 5 mg/kg; i.v.). Representative flow cytometric plots of CD8⁺ T cells in tumors.
Biomaterials

Repair of spinal cord injury by inhibition of astrocyte growth and inflammatory factor synthesis through local delivery of flavopiridol in PLGA nanoparticles. [Abstract]

2014 Aug;35(24):6585-94. PMID: 24811262
Plant Cell

ZmSSRP1 facilitates the progression of RNA polymerase II and is essential for kernel development in maize. [Abstract]

2025 Apr 2;37(4):koaf071. PMID: 40166832
Int J Biol Sci

DDX24 Mutation Alters NPM1 Phase Behavior and Disrupts Nucleolar Homeostasis in Vascular Malformations. [Abstract]

2023 Aug 6;19(13):4123-4138. PMID: 37705750
Cell Commun Signal

Elevation of effective p53 expression sensitizes wild-type p53 breast cancer cells to CDK7 inhibitor THZ1. [Abstract]

2022 Sep 5;20(1):96. PMID: 36058938
Clin Cancer Res

Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors. [Abstract]

2020 Apr 15;26(8):2011-2021. PMID: 31937620
Proc Natl Acad Sci U S A

Cell division in the shoot apical meristem is a trigger for miR156 decline and vegetative phase transition in Arabidopsis. [Abstract]

2021 Nov 16;118(46):e2115667118. PMID: 34750273
Cell Chem Biol

Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity. [Abstract]

2019 Aug 15;26(8):1067-1080.e8. PMID: 31178407
Cell Chem Biol

Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors. [Abstract]

2018 Feb 15;25(2):135-142.e5. PMID: 29276047
Int J Biol Macromol

Trained immunity driven by Enterococcus faecalis ribosomal protein S11 enhances antigen presentation and boosts influenza vaccine efficacy via nanoparticle delivery. [Abstract]

2025 Jun;315(Pt 1):144179. PMID: 40381785
EMBO Mol Med

Isomeranzin activates Gnas-AMPK signaling to drive white adipose browning and curb obesity in mice. [Abstract]

2025 Nov 26. PMID: 41299101
Cell Rep

Mechanism of Virus Attenuation by Codon Pair Deoptimization. [Abstract]

2020 Apr 28;31(4):107586. PMID: 32348767
Cell Syst

A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. [Abstract]

2018 Apr 25;6(4):424-443.e7. PMID: 29655704
J Med Chem

Development of an In Silico Prediction Model for P-glycoprotein Efflux Potential in Brain Capillary Endothelial Cells toward the Prediction of Brain Penetration. [Abstract]

2021 Mar 11;64(5):2725-2738. PMID: 33619967
Sci Data

High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]

2024 Sep 19;11(1):1024. PMID: 39300112
Cell Mol Life Sci

TGF-β1 promotes epithelial-to-mesenchymal transition and stemness of prostate cancer cells by inducing PCBP1 degradation and alternative splicing of CD44. [Abstract]

2021 Feb;78(3):949-962. PMID: 32440711
EMBO Rep

CDK inhibitor Palbociclib targets STING to alleviate autoinflammation. [Abstract]

2022 Jun 7;23(6):e53932. PMID: 35403787
Am J Physiol Cell Physiol

Thrombopoietin Mitigates Neuronal Death by Enhancing Mitophagy and Suppressing NLRP3 Inflammasome Activation Under Oxygen-Glucose Deprivation Conditions. [Abstract]

2025 Aug 20. PMID: 40833847
ACS Omega

Total Synthesis of Rohitukine and Dysoline and Their Anticancer Analogues Flavopiridol and IIIM-290. [Abstract]

2025 Aug 16;10(33):38240-38254. PMID: 40893326
Molecules

Development and Validation of a Rapid LC-MS/MS Method for Quantifying Alvocidib: In Silico and In Vitro Metabolic Stability Estimation in Human Liver Microsomes. [Abstract]

2023 Mar 4;28(5):2368. PMID: 36903615
Sci Rep

Flavopiridol induces cell cycle arrest and apoptosis by interfering with CDK1 signaling pathway in human ovarian granulosa cells. [Abstract]

2024 Oct 31;14(1):26239. PMID: 39482384
Sci Rep

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells. [Abstract]

2021 Mar 8;11(1):5374. PMID: 33686114
Sci Rep

Evidence for transcriptional interference in a dual-luciferase reporter system. [Abstract]

2015 Dec 1:5:17675. PMID: 26620302
Cancers (Basel)

Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening. [Abstract]

2022 Mar 19;14(6):1575. PMID: 35326726
iScience

Transcriptional synergy in human aortic endothelial cells is vulnerable to combination p300/CBP and BET bromodomain inhibition. [Abstract]

2024 May 16;27(6):110011. PMID: 38868181
J Virol

2026 May 11.
PLoS Genet

Myeloid Targeted Human MLL-ENL and MLL-AF9 Induces cdk9 and bcl2 Expression in Zebrafish Embryos. [Abstract]

2024 Jun 3;20(6):e1011308. PMID: 38829886
Int J Med Sci

NCAPH Promotes the Proliferation of Prostate Cancer Cells Via Modulating the E2F1 Mediated PI3K/AKT/mTOR Axis. [Abstract]

2025 Jan 27;22(4):940-954. PMID: 39991770
ACS Chem Biol

A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family. [Abstract]

2017 May 19;12(5):1245-1256. PMID: 28263556
Toxicol Lett

Flavopiridol inhibits oocyte maturation, reduces oocyte quality and blocks cumulus cell function. [Abstract]

2024 Nov:401:44-54. PMID: 39276810
Biochem Biophys Res Commun

CDK9 modulates circadian clock by attenuating REV-ERBα activity. [Abstract]

2019 Jun 11;513(4):967-973. PMID: 31005255
Turk Neurosurg

Intrathecal Administration of Flavopiridol Promotes Regeneration in Experimental Model of Spinal Cord Injury. [Abstract]

2016;26(6):922-929. PMID: 27476919
Albert Einstein College of Medicine

2026.
bioRxiv

ATM promotes reversed fork processing during DNA interstrand cross-link repair. [Abstract]

2025 Oct 9:2025.10.08.680157. PMID: 41279244
bioRxiv

2025 Aug 19.
University of Washington

2025.
bioRxiv

Mapping and engineering RNA-controlled architecture of the multiphase nucleolus. [Abstract]

2024 Sep 29:2024.09.28.615444. PMID: 39386460
bioRxiv

2024 July 27.
Research Square Preprint

2024 May 2.
Research Square Preprint

2024 Apr 2.
bioRxiv

2024 Mar 17.
bioRxiv

2023 Sep 7.
Purdue University

2022.
The University of Chicago

2022 Aug.
Research Square Preprint

2022 Jan.
Free University of Berlin

2021 Mar.
University of North Carolina at Chapel Hill

2020 Jun.

Solvent & Solubility

In Vitro:

DMSO : ≥ 20 mg/mL (45.63 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : ≥ 20 mg/mL (45.63 mM)

DMF : 7.69 mg/mL (17.55 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2815 mL

11.4077 mL

22.8154 mL

5 mM

0.4563 mL

2.2815 mL

4.5631 mL

10 mM

0.2282 mL

1.1408 mL

2.2815 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.67 mg/mL (1.53 mM); Clear solution

This protocol yields a clear solution of ≥ 0.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.67 mg/mL (1.53 mM); Clear solution

This protocol yields a clear solution of ≥ 0.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 5%DMSO 95%(10%Tween80 in Saline)

Solubility: mg/mL; null solution; Need ultrasonic and warming and adjust pH toMSwithMSO

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Protocol

Kinase Assay^[1]

Briefly, lysates containing approximately 3×10⁶ cells are incubated with 50 μM LEVD-AFC (caspase 4 substrate) or LETD-AFC (caspase 8 substrate) containing 10 mM dithiothretiol (DTT). Caspase 4 activity is measured one hour after addition of substrate and caspase 8 activity is measured 30 minutes after addition of substrate. Release of free AFC is measured with a Beckman-Coulter DTX 880 multimode detector.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[1]

The cells treated with flavopiridol are washed after 4 hours with PBS and resuspended in regular growth medium (RPMI 1640) supplemented with 10% human serum and antibiotics for the remainder of the incubation time. In the case of flavopiridol/chloroquine samples, chloroquine is re-added in the fresh media after flavopiridol is washed at 4 hours. For all the other conditions, cells are incubated with the respective drugs for 24 hours continuously.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Mahoney E, et al. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.Blood. 2012 Aug 9;120(6):1262-1273. [Content Brief]

[2]. Keskin H, et al. Complex effects of flavopiridol on the expression of primary response genes. Cell Div. 2012 Mar 29;7:11. [Content Brief]

[3]. Kim KS, et al.Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. J Med Chem. 2000 Nov 2;43(22):4126-34. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMF / DMSO / H₂O	1 mM	2.2815 mL	11.4077 mL	22.8154 mL	57.0386 mL
	5 mM	0.4563 mL	2.2815 mL	4.5631 mL	11.4077 mL
	10 mM	0.2282 mL	1.1408 mL	2.2815 mL	5.7039 mL
	15 mM	0.1521 mL	0.7605 mL	1.5210 mL	3.8026 mL
DMSO / H₂O	20 mM	0.1141 mL	0.5704 mL	1.1408 mL	2.8519 mL
	25 mM	0.0913 mL	0.4563 mL	0.9126 mL	2.2815 mL
	30 mM	0.0761 mL	0.3803 mL	0.7605 mL	1.9013 mL
	40 mM	0.0570 mL	0.2852 mL	0.5704 mL	1.4260 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Flavopiridol Hydrochloride

54 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Flavopiridol Hydrochloride

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

RNA Binding Bioactive Compound Library

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Antiviral Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Endoplasmic Reticulum Stress Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Rare Diseases Drug Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

MCE Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Flavopiridol Hydrochloride

All CDK Isoforms

All HIV Isoforms

Biological Activity

Chemical Information

Publications (54)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Flavopiridol Hydrochloride Related Classifications

HY-10006 Related Classifications